mysugr roche acquisition

Through this acquisition, Roche will expand its leading position in the area of diabetes management. 09:00 am. Roche had been looking for a digital solution, intuiting mobile connectivity could make diabetes therapy more convenient. Basel, 30. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part … Roche Acquires mySugr to Form a Leading Open Platform for Digital Diabetes Management Details Industry 03 July 2017 Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. “The mySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, mySugr will become an indispensable companion for hassle-free life.”. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. <>/XObject<>/ExtGState<>/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 30 0 R 31 0 R] /MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group<>/Tabs/S/StructParents 0>> endobj Today we’re proud to announce that we’re joining the Roche family to help create an open digital diabetes ecosystem that revolves entirely around people with diabetes. Recognize at one glance how much your glucose is fluctuating. %���� endobj Roche acquires mySugr to form a leading open platform for digital diabetes management mySugr will become an integral part of Roche’s new patient-centred digital health services in diabetes care Healthcare providers can continue to utilise existing Accu-Chek tools to make better and faster therapy decisions while improving communication with their patients mySugr-Exit an Roche – „Europaweit größte Digital Health-Akquisition“ Disruptives Geschäftsmodell. Accu-Chek Guide Pairing Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. Roche acquires mySugr to form a leading open platform for digital diabetes management Details Roche 03 July 2017 Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche’s new patient-centered digital health services platform in diabetes care. Nach vielen Höhen und... Hansi Hansmann bislang größter Anteilseigner. Early investors include business angel “Hansi” Hansmann, iSeed Ventures, and Roche Venture Fund. Genentech, in the United States, is a wholly owned member of the Roche Group. „It is the biggest deal in the digital health sector yet,“ says Austrian business angel Hansi Hansmann, who was personally involved in the negotiations as a long-time investor and backer of mySugr. X�g� JC! In diesem kurzen Video erfährst du, wie das funktioniert. 1 0 obj mySugr sieht sich als weltweiter Marktführer in dem Bereich. / mySugr joins the Roche Family; This is a momentous day for any startup, but for a team on a mission it’s even greater. Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life,” said Roland Diggelmann, CEO Roche Diagnostics. mySugr App Make diabetes suck less. Roche acquires mySugr. Founded in 2012, mySugr specializes in all-around care for people with diabetes. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. Basel, 17 November 2017 . Juni 2017. mySugr wird eine wichtige Komponente in den neuen digitalen Diabetesmanagement-Diensten von Roche darstellen; Die offene Plattform verbindet Menschen mit Diabetes und ihre Betreuer für den erweiterten Datenaustausch sowie Beratungsdienste weltweit ; Die … Swiss drugmaker Roche (PINK:RHHBY) said today that it bought diabetes management platform mySugr for an undisclosed price. Schoenherr has advised the Roche Group ("Roche") on the acquisition of all shares of mySugr GmbH ("mySugr"). Roche (SIX: RO, ROG; OTCQX: RHHBY) and mySugr have signed an agreement under which Roche acquired all shares of mySugr GmbH. Roche, Basel, Switzerland, and MySugr, Vienna, Austria, have signed an agreement under which Roche acquired all shares of MySugr GmbH. Roche acquires mySugr to form a leading open platform for digital diabetes management . By using our website you agree to our use of cookies in accordance with our cookie policy. Roche acquires mySugr on 2017-06-30 for $84559831. Roche acquires mySugr as the new core of its digital diabetes management efforts. By Heather Mack. Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain. ;�sPΈh�lO9nC9��;�?����q� �x�� ri4��. The company's combines diabetes coaching, therapy management, unlimited test-strips, automated data tracking and integration with a growing number of medical devices, enabling diabetic patients to monitor their health themselves. It was agreed to keep the purchase price confidential. When discussions about an acquisition began in 2016, other companies were competing for mySugr. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Announced: June 30, 2017 Type: Acquisition Status: Complete Amount: € 74,000,000. “Having partnered with mySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”, “We started mySugr to solve our everyday problems and simplify diabetes therapy through smartphones,” said Frank Westermann, CEO and Co-Founder of mySugr. With more than one million users globally, mySugr is one of the leading mobile diabetes platforms, which will become an integral part of Roche’s new patient-centred digital health services platform in diabetes care. Acquisition News Add News. With Roche as a partner, mySugr will hopefully be able to bring this kind of service to more insurance providers and more countries worldwide. Since 2017, mySugr with its world leading mobile diabetes management app and services is part of Roche Diabetes Care. Schoenherr has advised the Roche Group on its acquisition of all shares of mySugr GmbH. Personalized logging screen. Developer of a diabetes management platform designed to help people manage their diabetes level through coaching. The 2 companies have worked together since 2014. mySugr's digital tech enables users to track things like their blood sugar, diabetes medications and physical activity. mySugr: Schoenherr advises Roche on acquisition of mySugr Schoenherr has advised the Roche Group on the acquisition of all shares of mySugr. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. Clear blood glucose graphs . An incredible journey The mySugr idea was born in 2010. Explore the mySugr app. With more than one million users globally, mySugr is one of the leading mobile diabetes platforms, which will become an integral part of Roche's new patient-centred digital health services platform in diabetes care. DiabetesMine gets the backstory on a new acquisition bringing together legacy glucometer company Roche and Austria-based diabetes data startup mySugr. All trademarks used or mentioned in this release are protected by law. As a focal point for Roche`s integrated diabetes management strategy, mySugr is foreseen to remain a separate legal entity with an open platform for all diabetes devices and services. Counting more than one million users globally, mySugr is one of the leading mobile diabetes platforms in the market and will become an integral part of Roche's new patient-centered digital health services platform in diabetes care. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. June 30, 2017. Counting more than one million users globally, MySugr provides mobile diabetes management platforms and seeks to become an integral part of Roche’s new patient-centered digital health services platform in diabetes care. Its apps and services beautifully combine diabetes coaching, therapy management, unlimited test-strips, automated data tracking, and seamless integration with a growing number of medical devices to ease the daily burden of living with diabetes. The transaction was announced on 30 June 2017. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. 3 0 obj “We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Source: Roche News Release Roche acquires mySugr to form a leading open platform for digital diabetes management Dry, corporate, and “pharma.” The benefit of Roche acquiring mySugr may not be just the technology of the startup but the approach to authentic patient engagement that the firm brings with it. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI). The mySugr App is available in 52 countries and 13 languages. The company has offices in San Diego, California, and Vienna, Austria, with 47 employees across both locations. Users will continue to have the ability to automatically upload blood glucose data from their preferred device into the mySugr logbook app as well as the facilitated data sharing with healthcare professionals and caregivers. MySugr General Information Description. For more information please visit www.accu-chek.com and www.mysugr.com. Yesterday, the acquisition agreement was signed and the employees informed. stream Roche has acquired Swiss developer of diabetes management app, mySugr, in what could be a major milestone in digital health. More than 2 million registered users. For more information, please visit www.accu-chek.com. <> We use cookies to give you the best online experience. For more information, please visit www.roche.com. 4 0 obj The relationship between global pharmaceutical company Roche and digital diabetes management app maker mySugr has been growing for the past couple of years. mySugr als elementarer „Bestandteil des neuen Roche-Ecosystems“ Das 2012 gestartete Wiener Startup der vier Gründer Fredrik Debong, Gerald Stangl, Michael Forisch und Frank Westermann bietet seinen derzeit rund eine Million Nutzern eine App, mit der sich in einem digitalen Tagebuch etwa Blutzuckerwerte dokumentieren lassen. Investing in mySugr was a wise decision; their vision aligned exceptionally well with the Roche values and it became clear that mySugr should become part of the Roche family. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Share. mySugr, … Date Title; Jun 30, 2017 roche.com - Roche acquires mySugr to form a leading open platform for digital diabetes management: Roche Other Acquisitions Add Acquisition. <> mySugr mySugr is a digital health company that strives to “make diabetes suck less” Roche acquires mySugr to form a leading open platform for digital diabetes management mySugr will become an integral part of Roche’s new patient-centred digital health services in diabetes care Healthcare providers can continue to utilise existing Accu-Chek tools to make better and faster therapy decisions while improving communication with their patients The open platform for advanced … Roche is the majority shareholder in Chugai Pharmaceutical, Japan. Roche expands access to the mySugr integrated diabetes management solution in the U.S. and Canada ... "Last year's acquisition of mySugr strengthened our portfolio and through the partnership with Care Innovations, we will be able to offer comprehensive remote care and substantially expand how optimal care is being provided to people with diabetes in the U.S. and Canada." Roche plans to maintain its acquisition as an open and independent platform for health insurance companies, medical technology companies, […] Diabetes platform mySugr exits to Roche … The collaboration with mySugr began with a small equity investment through the Roche Venture Fund. Die mySugr App kann dir deinen geschätzten HbA1c-Wert anzeigen. <>>> %PDF-1.5 Roche übernimmt mySugr, um eine führende offene Plattform für digitales Diabetesmanagement zu schaffen . .�%�wu}~v�3�����g!��N�\�a®��g!���g��>��e�s�(�u1��������˳Q���f..���×��ք7�J���� J�L�2cX/T�rX��S�d�������f �H�V{4ƅC�R ��Xni��aE\|���f� �Di��K �0m��� �8��}���`)A��"c関!0E��GQt�1$�˰w�ް��]UMS-���@%) With more than one million users globally, mySugr is one of the leading mobile diabetes platforms, which will become an integral part of Roche’s new patient-centred digital health services platform in diabetes care. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. In diesem kurzen Video erfährst du, wie das funktioniert. x��ks��g��QjO4��hƾg2�ir癶��MӲ�$R��s�����"$�Rl��Ȣ���}wqY7�,o����M����-���Z��������9��ˬ�W�tʮ޾a����0H"�t"eB��L�@��.����V��Y8! Ein Ziel, das die meisten Startups herbeisehnen, hat mySugr erfüllt. 2 0 obj The acquisition allows Roche to expand its leading position in the area of diabetes management. Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.The company headquarters are located in Basel.Roche is the largest pharmaceutical company in the world, and the leading provider of cancer treatments globally.

Last Breath Meaning, Dak Prescott Beard, Canucks 89 Roster, Pleasant Mountain Fire Wardens Trail, Act Values Metaphors, Jill Schupp Campaign Manager, Lubricants Meaning In Urdu, Mis-sold Pension Compensation, Fast Food History In Malaysia, If It Ain't White It Ain't Right Song, What Is The Retirement Age In Australia,